Advertisement

Topics

AstraZeneca to highlight its commitment to blood cancers at 2017 ASH meeting

08:56 EST 7 Dec 2017 | PharmaBiz

AstraZeneca along with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in

Original Article: AstraZeneca to highlight its commitment to blood cancers at 2017 ASH meeting

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca to highlight its commitment to blood cancers at 2017 ASH meeting"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...